Streptococcus pneumoniae diseases are a rare but increasingly recognized trigger of atypical haemolytic uraemic syndrome (HUS) in young children and associated with a higher mortality rate than diarrhoea-associated HUS. This study aimed to determine the importance of neuraminidase A (NanA) and genomic diversity in the pathogenesis of pneumococcal HUS (pHUS). We investigated the nanA gene sequence, gene expression, neuraminidase activity and comparative genomic hybridization of invasive pneumococcal disease (IPD) isolates from patients with pHUS and control strains matched by serotype and sequence type (ST), isolated from patients with IPD but not pHUS. The nanA sequence of 33 isolates was determined and mutations at 142 aa positions were identified. High levels of diversity were observed within the NanA protein, with mosaic blocks, insertions and repeat regions present. When comparing nanA allelic diversity with ST and disease profile in the isolates tested, nanA alleles clustered mostly by ST. No particular nanA allele was associated with pHUS. There was no significant difference in overall neuraminidase activity between pHUS isolates and controls when induced/uninduced with Nacetylneuraminic acid. Comparative genomic hybridization showed little difference in genetic content between the pHUS isolates and the controls. Results of gene expression studies identified 12 genes differentially regulated in all pHUS isolates compared with the control. Although neuraminidase enzyme activity may be important in pHUS progression and contribute to pathogenesis, the lack of a distinction between pHUS isolates and controls suggests that host factors, such as acquired abnormalities of the alternative complement cascade in young children, may play a more significant role in the outcome of pHUS.
INTRODUCTION
Pneumococcal haemolytic uraemic syndrome (pHUS) is characterized by features that include the classic triad of microangiopathic haemolytic anaemia, thrombocytopenia and acute kidney injury. It accounts for some 5 % of HUS cases (Mizusawa et al., 1996) , although some reports suggest an increasing prevalence (Cabrera et al., 1998; Constantinescu et al., 2004; Waters et al., 2007) . pHUS differs from 'classic' HUS, associated with verocytotoxinproducing Escherichia coli for example, by an absence of a diarrhoeal prodrome, a younger age group (,2 years), an increased likelihood of requiring renal dialysis and prolonged hospitalization, a mortality rate of 19-50 % and poorer longterm prognosis with approximately 50 % of survivors with long-term renal dysfunction (Nathanson & Deschânes, 2001; Copelovitch & Kaplan, 2008) . pHUS cases usually present with either meningitis or pneumonia prior to developing HUS and comprise approximately 0.4-0.6 % of all invasive pneumococcal infections (Kaplan et al., 1998; Constantinescu et al., 2004; Lee et al., 2006; Copelovitch & Kaplan, 2010; Banerjee et al., 2011 ). An increased incidence of pHUS, linked with the emergence of serotype 19A pneumococcal clones, has been suggested (Banerjee et al., 2011) .
Pneumococcal neuraminidase activity has been postulated as the major trigger event in pHUS (Coats et al., 2011) . Pneumococci harbour three neuraminidase genes in varying frequency within the pneumococcal population with all strains carrying neuraminidase A (nanA), 96 % nanB and 51 % nanC (Pettigrew et al., 2006) . A key event in pHUS (termed T-activation) is the ability of NanA to cleave terminal N-acetyl neuraminic acid (sialic acid) from glycoproteins present on erythrocytes, glomerular endothelial cells, renal epithelial cells and platelets, thereby exposing the ThomsenFriedenreich antigen (T-antigen, Galb1-3GalNAc) (Klein et al., 1977; Crookston et al., 2000; Krysan & Flynn, 2001; Coats et al., 2011) . The T-antigen in turn binds autologous anti-T IgM, present in the plasma of all individuals from approximately 6 months of age onwards. Interaction of anti-T IgM is generally thought to be responsible for subsequent pathological events, although it seems likely that haemolysis observed in pHUS is a consequence of microangiopathic haemolytic anaemia rather than T-activation of red blood cells (Kim et al., 1979; Seger et al., 1980; McGraw et al., 1989) .
This study aimed to determine if pneumococcal isolates from cases of pHUS were overexpressing neuraminidase (NanA) or possessed increased neuraminidase (NanA) enzymic activity compared with control strains matched by serotype and sequence type (ST), isolated from patients with invasive pneumococcal disease (IPD), but not pHUS. In addition we investigated the properties of the nanA gene and NanA activity in a cohort of isolates from pHUS and controls by examining genomic differences and gene expression studies between these two groups of isolates using microarray technology.
METHODS
Isolates. The isolates used in this study were provided by the Respiratory & Vaccine Preventable Bacteria Reference unit, Public Health England (PHE), Scottish Haemophilus, Legionella, Meningococcus and Pneumococcus Reference Laboratory (SHLMPRL) and Xenogen (Caliper Life Sciences) and can be found in Table 1 . The isolates selected for this study were nine pHUS isolates from a previous study (Waters et al., 2007) , and six control isolates matched by serotype and ST and isolated from patients with IPD but not pHUS (in italics in Table 1 ). Also included for comparison were four isolates from a pneumococcal carriage/invasive study (Brueggemann et al., 2003) , 12 isolates with fully annotated genome sequence (Dopazo et al., 2001; Tettelin et al., 2001; Hiller et al., 2007) and a bioluminescent Salmonella pneumoniae strain, A66.1 Xen. The reference isolate D39 as a positive control, and a nanA knockout in a D39 background (DnanA), were constructed by allelic replacement of the full nanA gene with an erythromycin cassette, using primers 25X, 25Y, 27J and 27K, found in Table 2 .
nanA allele analysis. Amplification of nanA genes for sequencing was achieved by PCR with primers 31R and 31S (Table 2) . Purification and sequencing of nanA genes were carried out at the Sir Henry Wellcome Functional Genomics Facility at the University of Glasgow, UK, using methods described previously (Jefferies et al., 2007; Johnston et al., 2010) with the primers found in Table 2 . nanA sequences were also sourced from publicly available pneumococcal genomes and were assembled and translated into proteins using VectorNTI software (Life Technologies Corporation). Alleles were aligned to WT D39 allele, and assigned an allele number.
NanA assay. The neuraminidase activity of pneumococcal isolates was measured using a method described previously (Manco et al., 2006) , with modifications. Isolates were grown to mid-exponential phase [optical density (OD) of 0.6 at 600 nm] in brain heart infusion medium (BHI; Oxoid). Induction was achieved by growth in BHI+N-acetylneuraminic acid (Neu5ac) (50 mg ml
21
). Pellets from 20 ml mid-exponential growth culture were tested for neuraminidase activity, and culture supernatant was also tested, after concentrating 20-fold using an Amicon centrifugal filter (Millipore). Sample plates were incubated for 30 min at 37 uC. For lysates and supernatants, activity was measured in nmol p-nitrophenol released (mg total cell protein) 21 h
.
Microarray studies and validation. Comparative genomic hybridizations and gene expression studies were performed on the six serotype 19A, ST199 isolates in the study, four of which were pHUS isolates and two of which were controls. Microarray studies were carried out using the S. pneumoniae SPv1.1.0 microarrays, designed and produced by the Bacterial Microarray Group, St Georges, University of London, UK (BmG@S). These represent all ORFs from the genomes of TIGR4 and R6. The array design is available in BmG@Sbase (accession number A-BUGS-14; http://bugs.sgul.ac.uk/ A-BUGS-14) and also ArrayExpress (accession number A-BUGS-14). Both DNA and RNA hybridizations were carried out as per standard BmG@S protocols. For comparative genomic hybridizations, reciprocal dye swaps were performed. For expression studies, triplicate biological replicates were performed. In all cases, bacteria were incubated at 37 uC in BHI to mid-exponential phase (OD 600 50.6) before harvesting the DNA or RNA for microarrays (Johnston et al., 2010) . Validation of comparative genomic hybridizations was by PCR using primers used to design the microarray probes. Validation of expression studies was by reverse transcriptase (RT)-PCR using a Lightcycler 480 (Roche), with analysis using a previously described method using Qgene 4.0 software (Qgene) (Muller et al., 2002) . Fully annotated microarray data have been deposited in BmG@Sbase (accession number E-BUGS-72; http://bugs.sgul.ac.uk/E-BUGS-72) and also ArrayExpress (accession number E-BUGS-72).
Statistical analyses. Microarray slides were scanned using ScanArray Express (Packard Biosciences), feature extraction and normalization were carried out using BlueFuse for Microarray 3.5 software (Bluegnome Ltd), and statistical analysis to identify genes differentially expressed between test and control isolates was undertaken by ANOVA with Benjamini and Hochberg false discovery rate correction using GeneSpring GX 7.3.1 (Agilent Technologies) software. Further analyses of microarray data were carried out in GeneSpring GX 7.3.1 using a statistical ANOVA, with a false discovery The diversity present in each allele is represented by the presence of diversity regions identified previously (Johnston et al., 2010) . Strains highlighted in bold were isolated from pHUS in a previous study (Waters et al., 2007) 
RESULTS

Diversity present in the NanA protein
The nanA sequence of 33 isolates was determined (Table  1) , and mutations at 142 aa positions were identified, representing 13.7 % of positions in the WT protein.
Eighteen protein alleles were recognized, possessing three regions of diversity corresponding to previously identified mosaic blocks A, C and D (King et al., 2005) with two variants present in each of these regions. Furthermore, two insertion regions and a region of 20 aa repeats were identified. These have also been identified previously (Cámara et al., 1994) . A variety of point mutations were also present, although none occurred in essential residues. The isolates tested in this study, the nanA alleles identified and the diversity regions present in each allele can be found in Table 1 . When comparing nanA allelic diversity with ST and disease profile in the isolates tested, nanA alleles clustered mostly by ST (Table 1) . Therefore, no particular nanA allele was associated with pHUS.
NanA activity of pHUS and matched controls
The activity of cell wall-associated and secreted neuraminidase was measured in the nine pHUS isolates and six matched controls either with or without addition of Neu5ac in the growth medium. There was no significant difference in overall neuraminidase activity between pHUS isolates and controls when induced (P50.78) or uninduced with Neu5ac (P50.95) (Fig. 1) . Therefore, pHUS isolates did not possess greater neuraminidase activity or increased sensitization to induction by the substrate than control isolates. To provide some insight into the role of the related neuraminidase enzymes NanB and NanC, the results of assays on the NanA knockout demonstrated a significant decrease in overall neuraminidase activity (P50.0022).
Analysis of genetic content and gene expression in HUS isolates and controls
Comparative genomic hybridization showed little difference in genetic content between the pHUS isolates and the controls (including nanC where present). This implied that there is no association between genetic content and the ability to cause pHUS. When comparing the expression of the nanA gene between HUS isolates and matched controls, there was no significant difference in expression levels (P50.25). When comparing these levels of nanA gene expression with the reference isolate TIGR4, there was a significant decrease in expression in the tested isolates (P50.0007). There was also a significant decrease in nanB expression when the test isolates and controls were compared with TIGR4 (P50.0002). Although the nanC gene was expressed in the isolates from patients with pHUS and in the non-pHUS matched control isolates, when the levels of RNA expression were compared by hybridization against a common standard (TIGR4 RNA), there was no significant upregulation or downregulation of nanC expression between the pHUS-related and non-pHUS control isolates.
The results of the gene expression study identified 12 genes differentially regulated in all pHUS isolates compared with controls (Table 3) . Genes downregulated include those encoding the phosphomevalonate kinase mvaK2, a NifU family protein and the competence-inducable protein CinA. Upregulated genes included those encoding a RecF protein and ABC-N/P, the ATP-binding permease protein of an ABC transporter. Two genes, gdhA (upregulated) and guaA (downregulated), were involved in the glutamate metabolic pathway and their differential regulation resulted in increased glutamine and glutamate metabolism in pHUS isolates. Expression levels of these two genes were confirmed by RT-PCR (data not shown).
DISCUSSION
S. pneumoniae is an increasing cause of atypical HUS with relatively little known about the pathogenesis of this disease, although pneumococcal neuraminidase activity has been hypothesized to play a role (Crookston et al., 2000; Copelovitch & Kaplan, 2008; Coats et al., 2011) . More recent work (Coats et al., 2011) has supported this hypothesis in vivo by demonstrating in a mouse model GAGGAACAGTATGAATCGGAGTG  25X  TCTTATGATTTCGTATCAGC  25Y  AATAGCATAAGCTGATGTCC  27J  GGCGCGCCCTAACAGCTTTCTTCCTTGG  27K  AGCTGTTAGGGCGCGCCTGAAATAAGACATTT  31R  TAACAGTACACCTTGACTGC  31S  GTGTTCGATAAGGATTGAGC  35E  TGACCGCTTCTCCAGCATGC  35F  GAAACCAATGCTTCAAATGG  38P  TCCTCAGTAATGCAGGTGGAC  38Q  TGGAGCCTTGTTGACCAATAC  62F  CCAGAAGAGGTACAAAAACGTAGTCAAC  62G  AGGGTGATCTATACAAGGGTGACCA  62H  TGCCTTTGGTTTTCGGAACTTT  62I  CCCCTTCTTGAGCTAAAACAGGAGA  62J  AATCTTTACAAAGGTCAGGAATTGATT  62K  GCCGTCTTCATTCTAGTGACTGGGG  62L  CAACAAACCAAATAAAGATGGAAT  64I  GAATAAATGTCTTATTTCAGAAATC  64J  TTATTGTTCTCTCTTTTTCCCTAGC the role of pneumococcal NanA for exposure of the Tantigen during pneumococcal infection. An increased likelihood of pHUS isolates to carry the nanC gene compared with non-pHUS isolates, together with a link to serotype 3 pneumococci, has been reported (Janapatla et al., 2013) . The work reported in the current study, albeit under in vitro conditions, could not find any association between the sequences of the nanA alleles and the ability of the pneumococcal isolates from which they came to cause pHUS. Furthermore, no correlation was found between neuraminidase activity, induction potential or expression of nanA or nanB genes with an isolate's ability to cause pHUS. The failure to detect any significant neuraminidase activity in the nanA knockout suggests minor roles for nanB and nanC under the conditions used in this study. Compared with the work of Janapatla et al. (2013) our results may differ due to the type of isolates analysed since our cohort only contained one serotype 3 (ST180) pHUS strain and the apparent association of nanC with HUS could be a local epidemiological link between ST180 with Fig. 1 . Results of the neuraminidase assay, either uninduced (a) or induced with the substrate Neu5ac (a). Test isolates (15) were included in the assay as well as positive control D39 and nanA knockout strain D39 DnanA. Results were separated into neuraminidase activity from cell wall-associated enzyme (black) or secreted enzyme (grey). Results are calculated from triplicate repeats in each isolate. pNP, p-nitrophenol. (Janapatla et al., 2013 ).
An analysis of diversity of the nanA gene of S. pneumoniae revealed high levels of sequence diversity, in agreement with the findings of a previous study of the nanA gene (King et al., 2005) . This diversity was expected due to the surface-exposed nature of the NanA protein (Cámara et al., 1994) presumably resulting in selective pressure exerted by exposure to the host immune system. Despite the high levels of diversity present, all residues previously identified as essential (Cámara et al., 1994; Yesilkaya et al., 2006) were fully conserved across all protein alleles.
The results of the gene expression studies showed changes in the expression of genes gdhA and guaA, which would result in increased cellular levels of both glutamate and glutamine, which are the main nitrogen donors in the pneumococcal cell (Kloosterman et al., 2006) . gdhA, which is also involved in nitrogen metabolism, is independently repressed by both the nitrogen regulatory protein GlnR and the pleiotropic regulator codY, which seems to play a more important role (Kloosterman et al., 2006) . In Bacillus subtilus, codY is responsible for regulation of cellular nutritional and energy status (Kim et al., 2003; Shivers & Sonenshein, 2005) , and therefore gdhA has been suggested as an important control point for nutritional and energy regulation in the pneumococcal cell (Kloosterman et al., 2006) . The GlnR repressor is upregulated by high levels of ammonium ions and ammonia (Seger et al., 1980; Hendriksen et al., 2008) , which occurs in pHUS patients due to acute renal injury (Kim et al., 1979; Nath et al., 1991) . This would suggest that gdhA, repressed by GlnR, would be downregulated in pHUS patients. However the opposite was observed and neither glnR nor codY was differentially regulated in the pHUS isolates, implying that another unknown factor may regulate gdhA as well as guaA to result in increased glutamate and glutamine metabolism in pHUS isolates, and potentially regulate the energy status of the cell. It is possible that the S. pneumoniae exposed to altered environmental conditions present in pHUS patients is responsible for the observed alterations in gene expression. Such a response may represent a survival mechanism in these isolates and would be unlikely to be involved in initial pHUS pathogenesis.
The results of the comparative genomic hybridization showed genetic differences between the isolates tested, which shared serotype and ST, agreeing with previous findings of intra-ST diversity (Silva et al., 2006) . However, despite these observed differences, the isolates remained fairly clonal and there was no correlation between differences in genetic content and ability to cause pHUS, including neuraminidase genes. The clonality observed, along with recent findings of particular serotypes and STs commonly isolated from pHUS (Cabrera et al., 1998; Manco et al., 2006) , implied that although the control isolates were not isolated from pHUS, they may possess the virulence factors required to cause the disease. Therefore, although bacterial genetics may play a role, other factors such as host genetics or environmental factors probably have a more significant influence on which cases of IPD progress to cause pHUS. However, it is also possible that genetic elements essential for pHUS were missed as the isolates were only hybridized against genes present in the TIGR4 and R6 reference genomes. This represents one of the inherent limitations of microarray comparative hybridization studies.
The treatment of pHUS usually involves renal replacement therapy, although recent success has been observed with plasma exchange (Hopkins et al., 2008) . Interestingly there is some in vivo evidence that the administration of penicillin may facilitate development of pHUS by increasing the exposure of T-antigen (Erickson et al., 1994) . This study did not investigate the role of the host response to pneumococcal proteins such as through acquired abnormalities of the alternative complement cascade. This may be mediated through either neuraminidase activity or factor H binding sites (Ault, 2000) , pneumococcal Hic proteins that are structurally related immune evasion molecules that bind complement inhibition factor H (Jarva et al., 2004) or pneumococcal surface protein C interaction with factor H and complement (Zipfel et al., 2008) . This may all impact on pHUS development.
In conclusion, although an active neuraminidase enzyme is probably required to cause pHUS through facilitating exposure of T-antigen, this study observed no association between pHUS isolates and nanA allelic diversity, activity or expression. Despite observation of differentially regulated genes, the relative clonality of the pHUS and control isolates suggested that although bacterial genetics may be important, other factors in addition to T-antigen exposure are implicated, such as abnormalities of the alternative complement cascade (Dragon-Durey et al., 2004) . The young age (,2 years) of patients with pHUS suggests factors relating to developing host immunity or declining maternal passive immunity to pneumococcal and Tantigens coinciding with IPD.
